# Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

> **NCT01935934** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 102 (actual)

## Conditions studied

- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Metastatic Endometrioid Adenocarcinoma
- Recurrent Malignant Uterine Corpus Neoplasm
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
- Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
- Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
- Uterine Corpus Carcinosarcoma

## Interventions

- **DRUG:** Cabozantinib S-malate
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01935934
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-08
- **Primary completion:** 2019-09-12
- **Final completion:** 2024-10-24
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01935934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01935934, "Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01935934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*